Results For "NIV-Pune"

1 News Found

Covaxin well tolerated with no safety concerns: Lancet

News | November 12, 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%

Latest Stories

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

Vinod Paremal President & MD, Evonik, India Region

Packaging